Gwen Lapham, PhD, MPH, MSW, joined Kaiser Permanente Washington Health Research Institute (KPWHRI) in 2013 as an addictions health services researcher. Since then, she has capitalized on her prior social work and health services training to do impactful research on evidence-based primary care for unhealthy substance use, including alcohol, cannabis, and opioids. She has recently begun making strides in understanding cannabis use among primary care patients, including medical use and use among prenatal women.
Dr. Lapham recently completed the CATALyST K12 Washington Learning Health System Program funded by the Agency for Healthcare Research and Quality and the Patient-Centered Outcomes Research Institute. In the program, she partnered with Kaiser Permanente Washington health system leaders and with KPWHRI’s Center for Accelerating Care Transformation to address gaps in the quality of behavioral health care for children and adolescents by developing and testing an integrated approach to adolescent mental health. She expects this work to lead to new evidence for effective implementation of adolescent mental health integrated in primary care.
She is also a co-investigator of the Primary Care Opioid Use Disorders Treatment, or PROUD trial, a pragmatic implementation trial of nurse care management for treatment of opioid use disorders in primary care, as well as the Health Systems node of the National Institute on Drug Abuse Clinical Trials Network. Dr. Lapham’s research projects specific to cannabis include:
Prior to working at KPWHRI, Dr. Lapham focused on qualitative and quantitative evaluation of preventive alcohol interventions in medical settings at the Veterans Health Administration in Seattle.
Implementation research; quality measurement
Screening and brief intervention; mental health quality measurement
Prevention and treatment
The SPARC trial successfully implemented behavioral health care into primary care. On our website, you can access tools for behavioral health integration, as well as frequently asked questions and publications.
Yeung K, Richards J, Goemer E, Lozano P, Lapham G, Williams E, Glass J, Lee A, Achtmeyer C, Caldeiro R, Parrish R, Bradley K. Costs of using evidence-based implementation strategies for behavioral health integration in a large primary care system. Health Serv Res. 2020 Dec;55(6):913-923. doi: 10.1111/1475-6773.13592. PubMed
Matson TE, Lapham GT, Bobb JF, Johnson E, Richards JE, Lee AK, Bradley KA, Glass JE. Cannabis use, other drug use, and risk of subsequent acute care in primary care patients. Drug Alcohol Depend. 2020 Aug 8;216:108227. doi: 10.1016/j.drugalcdep.2020.108227. [Epub ahead of print]. PubMed
Williams EC, McGinnis KA, Rubinsky AD, Matson TE, Bobb JF, Lapham GT, Edelman EJ, Satre DD, Catz SL, Richards JE, Bryant KJ, Marshall BDL, Kraemer KL, Crystal S, Gordon AJ, Skanderson M, Fiellin DA, Justice AC, Bradley KA. Alcohol use and antiretroviral adherence among patients living with HIV: is change in alcohol use associated with change in adherence? AIDS Behav. 2021 Jan;25(1):203-214. doi: 10.1007/s10461-020-02950-x. PubMed
Bradley KA, Lapham GT, Lee AK. Screening for drug use in primary care: practical implications of the new USPSTF recommendation. JAMA Intern Med. 2020 Jun 9. doi: 10.1001/jamainternmed.2019.7335. [Epub ahead of print]. PubMed
Chavez LJ, Bonny AE, Bradley KA, Lapham GT, Cooper J, Miller W, Chisolm DJ. Medication treatment and health care use among adolescents with opioid use disorder in Ohio. J Adolesc Health. 2020 Apr 7. pii: S1054-139X(20)30043-4. doi: 10.1016/j.jadohealth.2020.01.016. [Epub ahead of print]. PubMed
Boudreau DM, Lapham G, Johnson EA, Bobb JF, Matthews AG, McCormack J, Liu D, Samet JH, Campbell CI, Rossom RC, Binswanger IA, Yarborough BJH, Arnsten JH, Cunningham CO, Glass JE, Murphy MT, Zare M, Hechter R, Ahmedani B, Braciszewski JM, Horigian VE, Szapocznik J, Samet JH, Saxon AJ, Schwartz RP, Bradley KA. Documented opioid use disorder and its treatment in primary care patients across six US health systems. J Subst Abuse Treat. 2020 Mar;112S:41-48. doi: 10.1016/j.jsat.2020.02.001. PubMed
Sayre M, Lapham GT, Lee AK, Oliver M, Bobb JF, Caldeiro RM, Bradley KA. Routine Assessment of Symptoms of Substance Use Disorders in Primary Care: Prevalence and Severity of Reported Symptoms. LID - 10.1007/s11606-020-05650-3 [doi] J Gen Intern Med. 2020 Jan 23. pii: 10.1007/s11606-020-05650-3. doi: 10.1007/s11606-020-05650-3 [Epub ahead of print] PubMed
Williams EC, Bobb JF, Lee AK, Ludman EJ, Richards JE, Hawkins EJ, Merrill JO, Saxon AJ, Lapham GT, Matson TE, Caldeiro R, Greenberg DM, Kivlahan DR, Bradley KA. Effect of a care management intervention on 12-month drinking outcomes among patients with and without DSM-IV alcohol dependence at baseline. J Gen Intern Med. 2019 Aug 20. doi: 10.1007/s11606-019-05261-7. [Epub ahead of print]. PubMed
Richards JE, Bobb JF, Lee AK, Lapham GT, Williams EC, Glass JE, Ludman EJ, Achtmeyer C, Caldeiro RM, Oliver M, Bradley KA. Integration of screening, assessment, and treatment for cannabis and other drug use disorders in primary care: an evaluation in three pilot sites. Drug Alcohol Depend. 2019 Aug 1;201:134-141. doi: 10.1016/j.drugalcdep.2019.04.015. Epub 2019 Jun 8. PubMed
Williams EC, McGinnis KA, Tate JP, Matson TE, Rubinsky AD, Bobb JF, Lapham GT, Edelman EJ, Catz SL, Satre DD, Bryant KJ, Marshall BDL, Kraemer KL, Bensley KM, Richards JE, Skanderson M, Justice AC, Fiellin DA, Bradley KA. HIV disease severity is sensitive to temporal changes in alcohol use: a national study of VA patients with HIV. J Acquir Immune Defic Syndr. 2019 Apr 6. doi: 10.1097/QAI.0000000000002049. [Epub ahead of print]. PubMed
1 in 5 people who use cannabis daily at risk for moderate to severe use disorder.
New grant funds crucial work to test effectiveness of teen suicide prevention in primary care.
Five years and 8 scholars later, KPWHRI celebrates the impact of the CATALyST training program on early-career scientists.
A trial led by KPWHRI researchers found that adding nurse care managers helped more people get needed treatment.
New findings indicate medical cannabis use is associated with a lower risk of moderate to severe cannabis use disorder.
Medscape, Dec. 19